Carisoprodol withdrawn

The EMEA has recommended suspension of the marketing authorisation for carisoprodol (Carisoma), a muscle relaxant indicated for treatment of acute musculo-skeletal disorders associated with muscle spasm.

The CHMP has concluded that there is a risk of abuse, addiction, intoxication and psychomotor impairment with carisoprodol and that there are effective alternatives with a better safety profile.

Prescribers should not issue any new prescriptions for carisoprodol and should switch patients taking the medicine to an alternative treatment if necessary

Further information: CHMP

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more